Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Ronald C. DeConti"'
Autor:
Pamela N. Munster, Daniel M. Sullivan, Anthony Neuger, Richard Lush, Frederick A. Hausheer, Sem Bastien, Douglas Marchion, Elona Bicaku, Ronald C. DeConti, Jana Dawson, Adil I. Daud
Supplementary Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d9697e5388a426a347a91ff8cd34505
https://doi.org/10.1158/1078-0432.22440090
https://doi.org/10.1158/1078-0432.22440090
Autor:
Pamela N. Munster, Daniel M. Sullivan, Anthony Neuger, Richard Lush, Frederick A. Hausheer, Sem Bastien, Douglas Marchion, Elona Bicaku, Ronald C. DeConti, Jana Dawson, Adil I. Daud
Purpose: The novel topoisomerase I inhibitor karenitecin (KTN) shows activity against melanoma. We examined whether histone deacetylase inhibition could potentiate the DNA strand cleavage, cytotoxicity as well as the clinical toxicity, and efficacy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6efe0e46b300c1561e799201cc208254
https://doi.org/10.1158/1078-0432.c.6517464.v1
https://doi.org/10.1158/1078-0432.c.6517464.v1
Autor:
Ricardo J. Gonzalez, Suroosh S. Marzban, Jane L. Messina, Tapan A. Padhya, C. Wayne Cruse, Christopher A. Puleo, Binglin Yue, Ronald C. DeConti, Amod A. Sarnaik, Michael J Carr, Jonathan S. Zager, Vernon K. Sondak, Michael J. Schell, Brooke L. Walls, Ryan S. Jackson, Franz O. Smith
Publikováno v:
Cancer. 121:3252-3260
BACKGROUND The purposes of this study were 1) to determine the impact of primary tumor-related factors on the prediction of the sentinel lymph node (SLN) status and 2) to identify clinical and pathologic factors associated with survival in Merkel cel
Autor:
Mark B, Faries, Nicola, Mozzillo, Mohammed, Kashani-Sabet, John F, Thompson, Mark C, Kelley, Ronald C, DeConti, Jeffrey E, Lee, James F, Huth, Jeffrey, Wagner, Angus, Dalgleish, Daniel, Pertschuk, Christopher, Nardo, Stacey, Stern, Robert, Elashoff, Guy, Gammon, Donald L, Morton, Frank, Senecal
Publikováno v:
Annals of surgical oncology. 24(13)
This phase III study was undertaken to evaluate the efficacy of an allogeneic whole-cell vaccine (Canvaxin™) plus bacillus Calmette-Guerin (BCG) after complete resection of stage IV melanoma. After complete resection of ≤5 distant metastases, pat
Autor:
Nikhil G. Rao, Tawee Tanvetyanon, Andy Trotti, Judith C. McCaffrey, Tapan A. Padhya, Ronald C. DeConti, Julie A. Kish
Publikováno v:
Head & Neck. 37:840-845
Background Despite resection followed by adjuvant radiotherapy, high-risk cutaneous squamous cell carcinomas of the head and neck region (SCCHN) often recur. Because adjuvant concurrent chemoradiation reduces recurrence among high-risk mucosal SCCHN,
Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma
Autor:
Gang Han, Ronald C. DeConti, Julie A. Kish, Tawee Tanvetyanon, Andy Trotti, Hinda Boutrid, Tapan A. Padhya, Judith C. McCaffrey, James T. May, Jimmy J. Caudell, Nikhil G. Rao, Thomas V. McCaffrey, Faisal Merchant, Roberto D. Sabater
Publikováno v:
Head & Neck. 35:1796-1800
Background Over the past decade, intensity-modulated radiation therapy (IMRT) has gained widespread use in the treatment of head and neck cancer. Methods All patients with squamous cell carcinoma of the oropharynx treated with primary IMRT with or wi
Publikováno v:
Seminars in Oncology. 39:163-172
Merkel cell carcinoma (MCC) is a highly aggressive skin malignancy. The growing incidence and recognition of this cancer in elderly or immunosuppressed individuals suggests that it is becoming an increasing clinical challenge. MCC recently has been d
Autor:
Arlene A. Forastiere, Rita Axelrod, Barbara Burtness, Ronald C. DeConti, Athanassios Argiris, Musie Ghebremichael
Publikováno v:
Cancer. 117:3374-3382
BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. METHODS: Eligibility criteria included in
Publikováno v:
Merkel Cell Carcinoma. :313-341
Publikováno v:
Merkel Cell Carcinoma. :i-xxxi